A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Sequential Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered GCC-4401C in Healthy Males
Phase of Trial: Phase I
Latest Information Update: 02 Jan 2018
Price : $35 *
At a glance
- Drugs GC 2107 (Primary) ; Rivaroxaban
- Indications Embolism; Stroke; Venous thromboembolism
- Focus Adverse reactions
- Sponsors GC Pharma; Green Cross
- 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
- 18 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 09 Oct 2013 New trial record